Elizabeth Burtman
Pediatric Endocrinology · Tenafly, NJNPI 1679866255
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.3%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Pfizer at 47.5% of the total. Reporting peaked in 2023 at $4,865 and has fallen 79.8% since, to $983 in 2025.
Across 348 payments — averaging $30.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$5K
- AbbVie$2K
- Novo Nordisk$1K
- Ascendis Pharma Endocrinology Inc$508
- Amneal Pharmaceuticals LLC$306
- Rhythm Pharmaceuticals, Inc.$183
- plus $2K from 21 others
What the payments were for
- Consulting fees$3,06029%
- Speaking & faculty fees$7407%
- Travel & lodging$4564%
- Food & beverage$6,00557%
- Education$1201%
- Gifts$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 48 | $4,977 |
| AbbVie | 84 | $1,576 |
| Novo Nordisk | 76 | $1,331 |
| Ascendis Pharma Endocrinology Inc | 25 | $508 |
| Amneal Pharmaceuticals LLC | 22 | $306 |
| Rhythm Pharmaceuticals, Inc. | 11 | $183 |
| Sandoz | 11 | $163 |
| Tolmar Pharmaceuticals, Inc. | 3 | $149 |
| Endo Pharmaceuticals Inc. | 10 | $135 |
| Tolmar, Inc. | 8 | $128 |
| Sanofi-aventis U.S. LLC | 1 | $121 |
| Arbor Pharmaceuticals, Inc. | 8 | $108 |
| Azurity Pharmaceuticals, Inc. | 6 | $103 |
| Intra-sana Laboratories | 1 | $100 |
| Endo USA, Inc. | 4 | $96 |
| Ferring Pharmaceuticals Inc. | 6 | $83 |
| Biomarin Pharmaceutical Inc. | 2 | $78 |
| IBSA Pharma Inc. | 5 | $72 |
| Soleno Therapeutics, Inc. | 4 | $69 |
| Ultragenyx Pharmaceutical Inc. | 3 | $48 |
| AstraZeneca | 3 | $45 |
| Neurocrine Biosciences, Inc. | 2 | $32 |
| Vivus LLC | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Galderma Laboratories, L.p. | 1 | $12 |
| Dexcom, Inc. | 1 | $12 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NGENLA$3,800
- Lupron Depot$238
- Sogroya$124
- FENSOLVI$123
- TZIELD$121
- SKYTROFA$118
- Wegovy$114
- Reltone 200 Mg$100
- Reltone 400 Mg$100
How this compares
$10,481 in reported general payments places this provider in the 85th percentile of 59 pediatric endocrinology providers in New Jersey.
Other pediatric endocrinology in Tenafly
- Richard HershcopfTenafly$28
- Lawrence SilvermanMorristown$492K
- Ahmed KhattabNew Brunswick$70K
- Ian MarshallNew Brunswick$51K
- Dennis BrennerWest Orange$39K
- Eric HuangBasking Ridge$23K
- Irene MamkinWest Orange$13K
- Javier AisenbergHackensack$10K
- Hope-Elizabeth ClennonNewark$8K
- Glenn GormleyBrick$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.